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Abstract
Antimicrobial resistance (AMR) is a global public-health emergency, which threatens the advances made by modern medical
care over the past century. The World Health Organization has recently published a global priority list of antibiotic-resistant
bacteria, which includes extended-spectrum b-lactamase-producing Enterobacteriaceae and carbapenemase-producing
Enterobacteriaceae. In this review, we highlight the mechanisms of resistance and the genomic epidemiology of these
organisms, and the impact of AMR.
INTRODUCTION
The development and introduction of antimicrobials in
the 20th century has transformed the delivery of modern
medical care. Yet, this ‘antibiotic golden-age’ is ending,
threatened by rising rates of antimicrobial resistance
(AMR) globally. Enterobacteriaceae, a family encompass-
ing many clinically important bacterial species, exhibits
rising levels of AMR. Infection with either extended-
spectrum b-lactamase-producing Enterobacteriaceae
(ESBL-E) or carbapenemase-producing Enterobacteriaceae
(CPE) is associated with increased mortality rates, time to
effective therapy, length of stay and overall healthcare
costs [1–8]. The impact of the continued spread of AMR
could have repercussions in multiple sectors. In the
healthcare sector itself, patient deaths resulting from AMR
are projected to reach 10million annually by 2050, but
AMR will also cause losses in the trillions to global eco-
nomic output [9]. ESBL-E and CPE have spread globally
[10, 11], and technologies such as whole-genome sequenc-
ing (WGS) are providing detailed insights into their evolu-
tion and dissemination. The World Health Organization
has recently published a global priority pathogens list to
focus attention on the most significantly resistant patho-
gens. Enterobacteriaceae resistant to third-generation
cephalosporins (which includes ESBL-E) and Enterobacter-
iaceae resistant to carbapenems (CRE) are included within
the critical category of this list [12].
ESBL-E
The definition of multidrug resistance is variable [13], but
Enterobacteriaceae exhibiting resistance to b-lactams,
extended-spectrum b-lactams and third-generation cephalo-
sporins are commonly recognized as ESBL-E [11, 14].
Extended-spectrum b-lactamase (ESBL) mechanisms them-
selves are classified based on their molecular structure or func-
tional similarities [15, 16] (Table 1). Initially, ESBL-E were
predominantly associated with nosocomial outbreaks, with
resistance arising from point mutations in plasmid-mediated
enzymes such as TEM-1, TEM-2, SHV-1 and OXA-10 [14].
CTX-M enzymes are now predominant. They arose via multi-
ple escape events of chromosomal b-lactamase-encoding
genes (blaklu) from Kluyvera spp. [17–19], supported by the
presence of transpositional units including ISEcp1 in CTX-M
groups 1, 2, 9 and 25 or ISCR1 in groups 2 and 9 [20]. Follow-
ing initial reports in Europe [21], South America [22] and
Japan [23], CTX-M enzymes have disseminated globally [24].
The group 1 enzyme CTX-M-15 is the most frequently identi-
fied, and dominates in many countries in Europe [25–30],
Asia [31, 32], Africa [33–35] and the USA [36, 37]. Additional
CTX-M mechanisms predominate in other locations. For
example, the group 9 enzyme CTX-M-14 is the leading mech-
anism in Escherichia coli in some areas of Korea [38] and
South America [39]. Until recently, CTX-M-14 was the major
mechanism across China [40–42], but a steady increase in
CTX-M-15 has also occurred [43–45].
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Genomic epidemiology demonstrates a number of wide-
spread lineages including sequence type (ST)131, ST38,
ST405 and ST10 in E. coli [46–49], and ST11, ST14 and
ST15 in Klebsiella pneumoniae [32, 50, 51]. ST131, an extra-
intestinal pathogenic E. coli, has undergone massive clonal
expansion and is strongly associated with the global dissem-
ination of the blaCTX-M-15 gene [47, 52, 53].
WGS has resolved ST131 into three clades, based upon the
presence of marker alleles for the type 1 fimbriae, fimH.
Clade A is associated with H41, clade B with H22 and H30
is associated with clade C [54–58]. A clade C sublineage is
the main driving force in the widespread dissemination of
CTX-M-15 and fluoroquinolone resistance (FQR) in ST131
[55, 56, 59]. Clade C is identifiable by FQR mutations in
gyrA (gyrA1AB) and parC (parC1aAB) genes, whereas
clades A and B are predominantly fluoroquinolone suscepti-
ble [55]. Further segregation of clade C into C1 and C2
occurs depending upon the presence of blaCTX-M-15 [56, 59].
Prior to the emergence of C1 and C2, acquisition of ele-
ments including the GI-pheV genomic island [54] and the
H30 allele [60] helped to prime ST131 for global success. C1
and C2 divergence and the development of FQR mutations
is estimated to have occurred in the late 1980s, consistent
with the introduction of fluoroquinolones for clinical use
[54]. CTX-M-14, CTX-M-27, CTX-M-19, CTX-M-24 and
CTX-M-55 have been identified in clade C [59]; however,
CTX-M-15 is almost entirely restricted to C2 [55, 56, 59].
Bayesian analysis based upon CTX-M variant distribution
also suggests blaCTX-M-15 emerged in ST131 following the
introduction of extended-spectrum cephalosporins into
clinical practice [59].
Plasmid movement between different species and lineages
represents a major source of AMR. blaCTX-M-15 in ST131 is
invariably associated with plasmids of incompatibility group
F (IncF) [25, 59, 61–63], although presence on IncN [64],
IncX [65] and IncI [66] plasmids has also been reported.
Specific IncF plasmids have been associated with C2 iso-
lates. This includes those with dual replicons, which compli-
cates plasmid typing and broadens the plasmid host range
[67, 68], additional AMR genes, gene cassettes, toxin/
IMPACT STATEMENT
The World Health Organization (WHO) has published a
global priority pathogens list of antibiotic-resistant bac-
teria, in order to increase the significance of and galva-
nize research into new treatments for particular
antibiotic-resistant pathogens. Of critical importance on
this list are carbapenem-resistant Acinetobacter bauma-
nii, Pseudomonas aeruginosa and Enterobacteriaceae.
Pathogens of this nature cause high morbidity and mor-
tality and increased healthcare costs. Carbapenem-
resistant Enterobacteriaceae encompasses a number of
genera, many of which harbour acquired multidrug-
resistance plasmids, which can carry and transmit
antimicrobial-resistance genes on an intra- and inter-
species level. This complicates surveillance, outbreak
investigations and actions by infection control professio-
nals. The spread of multidrug resistance is a globally
important problem, with several countries currently
reporting endemicity of highly resistant pathogens such
as carbapenem-resistant Klebsiella pneumoniae. We have
reviewed the current literature on carbapenem and
third-generation cephalosporin-resistant Enterobacteria-
ceae. Our review highlights the continued increasing
trend of resistance in Enterobacteriaceae and discusses
the mechanisms by which this occurs. We aim to provide
valuable collated information as part of a series of
reviews on the WHO priority pathogens and enhance the
current understanding in this area.
Table 1. Classification of b-lactamases
Adapted from Bush and Jacoby, 2010 [16].
Ambler molecular
class
Bush–Jacoby
group
Preferred substrate Inhibited Representative enzyme
A (serine
penicillinases)
2a Penicillins + PC1 from S. aureus
2b Penicillins, narrow-spectrum cephalosporins + TEM-1, TEM-2, SHV-1
2be Penicillins, narrow- spectrum and extended-
spectrum cephalosporins
+ SHV-2 to SHV-6, TEM-3 to TEM-26, CTX-Ms,
BEL-1, VEB-1, PER-1
2br Penicillins   TEM-30, SHV-72, SHV-19
2c Penicillins, carbenicillin + PSE-1
2e Extended-spectrum cephalosporins + FEC-1, CepA
2f Penicillins, cephalosporins, carbapenems +/  KPC-2, SME-1, NMC-A
B (MBLs) 3 Most b-lactams including carbapenems   IMP-1, VIM-1. NDM-1, CcrA and BcII, CphA, L1
C (cephalosporinases) 1 Cephalosporins   AmpC, CMY-2, ACT-1
D (oxacillinases) 2 Penicillins, cloxacillin +/  OXA-1, OXA-10
2de Extended-spectrum cephalosporins +/  OXA-11, OXA-15
2df Carbapenems +/  OXA-23, OXA-48
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antitoxin systems and stability mechanisms, all of which
may have influenced plasmid and clade success [57, 59, 69].
Architecture of the ST131 accessory genome, including plas-
mids, further supports clade-specific adaptations that have
likely contributed to the success of ST131 [70]. Multiple
clusters of variable accessory genome content within clade
C suggest that clonal expansions of stabilized accessory gene
profiles occur frequently, allowing generalization of this
highly structured clone [59, 70].
CPE
Rising ESBL-E prevalence correlates with increased carbape-
nem consumption [71, 72]; and appears to have driven the
emergence and spread of carbapenem resistance, especially
in Enterobacteriaceae [73]. Carbapenem resistance may be
caused by different mechanisms, including inducible
overexpression of chromosomal cephalosporinases, such as
AmpC, combined with porin loss [74]. More problematic,
however, is acquisition of carbapenemase genes via mobile
genetic elements. The most frequently identified mechanism
is the Ambler class A K. pneumoniae carbapenemase (KPC),
followed by class B metallo-b-lactamases (MBLs) such as
New Delhi MBL (NDM), and the class D OXA-type genes
[75] (Table 2, Fig. 1).
Since its identification in the USA in 1996 [76], KPC has
disseminated globally, has been reported to be present in
more than 50% of CPE in many countries, and in some
cases 100% of carbapenem-resistant K. pneumoniae [77–
84]. The majority of KPC-encoding genes are seen in
K. pneumoniae clonal group (CG)258, which includes the
successful lineages ST258 and ST11 [85–87]. An example of
this rapid dissemination can be seen in Greece. Following
the first KPC isolation in 2007 [88], KPC had spread to
most acute-care facilities within 2 years [89–92]. Most infec-
tions remain hospital-related, and associated with high
mortality rates [6, 93–95]. Many early cases were epidemio-
logically linked to travel to high prevalence locations [96–
101]; however, complex local transmission networks now
signify endemicity [102, 103]. More than 20 KPC variants
have been recognized, with blaKPC2 and blaKPC3 being the
most abundant [79, 83, 85, 104–106]. The gene is located in
isoforms of the 10 kb Tn4401 transposon [107], of the Tn3
transposon family [108, 109], and is associated with diverse
plasmids including IncFIIK [87], IncI [110], IncN [111],
IncL/M [112] and IncX [113].
Carbapenem-resistant lineages exhibit less diversity when
compared to carbapenem-susceptible Enterobacteriaceae
[114, 115] and lineages such as ST258 [112, 116, 117] and
ST11 [84, 106] demonstrate clonal spread. However, in con-
trast to the clonality of ESBL lineages and predominance of
a small number of globally disseminated epidemic lineages,
carbapenemase genes and plasmids show increased transfer-
ability within and between species, lineages, STs and
patients. This genetic mobility complicates the investigation
of outbreaks [114, 118–120]. This has been observed more
frequently in E. coli than other Enterobacteriaceae. The
spread of carbapenem resistance displays increased diversity
across STs, such as the large ST10 complex, rather than
strong association with existing global epidemic lineages
like ST131 [114, 121–123].
Non-clonal dissemination is also highly apparent in MBLs,
especially NDM. These class B enzymes, which include
NDM, GES, VIM and IMP, have also disseminated globally
[124]. MBLs hydrolyse all b-lactams, are not inhibited by b-
lactamase inhibitors, and their host bacteria often carry
additional resistance mechanisms such as ESBLs [125–128].
First identified in a Swedish patient repatriated from a New
Delhi hospital [129], most early cases had epidemiological
links to the Indian subcontinent [130–143]. Epidemic
spread and environmental contamination is evident in
India, Pakistan and Bangladesh [144, 145], whilst sporadic
cases or regional spread now occur on all continents [75, 84,
146, 147]. Clonal spread may occur during outbreaks [148,
149], but the high resolution of WGS enables tracking of
varying blaNDM-positive plasmids including IncA/C, IncF,
IncH, IncL/M, IncN and IncX types [113, 150–153], and
fluctuating genomic contexts flanking the blaNDM gene
among non-clonal isolates [128, 151, 154–156]. The blaNDM
gene is chimeric following fusion with the aminoglycoside
gene aphA6 and lies downstream of either entire, truncated
or remnants of the ISAba125 element [157].
blaVIM genes were originally described in Italian Pseudomo-
nas aeruginosa in the mid-1990s [158] and Enterobacteria-
ceae carrying blaVIM are predominantly reported in Europe
as occurring sporadically or in single hospital outbreaks
[147]. Sporadic cases are also seen in Africa, Taiwan, Mex-
ico, Saudi Arabia and the USA [159]. Since 2015, Hungary,
Italy and Spain have reported inter-regional spread; how-
ever, as with other CPE mechanisms, blaVIM is endemic in
Greece [147]. More than 48 variants have been identified
with blaVIM-1 and blaVIM-2 showing global dissemination
[159]. blaVIM genes are carried on variable class 1 integrons
within multiple plasmid Inc types [159–161].
blaIMP was the first described case of a transmissible carba-
penemase gene [162]; however, large-scale epidemiological
studies are lacking. The majority of blaIMP isolates originate
in the South Pacific [163] and Asia [164]. blaIMP is found
predominantly in K. pneumoniae, E. coli and Enterobacter
spp. on class 1 integrons [165]. Integrons and their gene
cassette combinations are variable and may show geograph-
ical correlations [164]. Despite being named due to imipe-
nem resistance, certain variants of blaIMP, particularly
blaIMP-6, actually exhibit low levels of imipenem resistance,
which may lead to misidentification, and contribute to the
lower detection rates of this mechanism [166, 167]. Geno-
mic evidence is now emerging of this mechanism moving
into epidemic Enterobacteriaceae such as E. coli ST131 [168,
169].
Finally, OXA-48 carbapenemases, first identified in 2001 in
Turkey, are also a public-health threat [170–172]. Owing to
their variable levels of carbapenem resistance, the spread of
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blaOXA-48 has been initially underestimated [173–175]. In
parallel to blaNDM and its Indian origins, blaOXA-48 was ini-
tially geographically linked to Turkey [171, 176]. However,
since 2015, multiple countries have inter-regional spread
and blaOXA-48 is endemic in Malta and Turkey [147]. Fur-
ther afield, extensively drug resistant (XDR) strains co-
harbouring blaNDM and blaOXA-48 have been identified in
the Middle East [177, 178], and blaOXA-48 strains have
emerged in Canada [173], Algeria [179] and Korea [180].
Shewanella spp. may be the natural progenitors of blaOXA-48
genes [181], which now predominantly appear in K. pneu-
moniae, E. coli and Enterobacter spp. [173, 182, 183].
blaOXA-48 is associated with the Tn1999 transposon, which
is composed of two copies of IS1999 bracketing the gene
[184, 185]. The majority of blaOXA-48 genes are associated
with Tn1999 or the variants Tn1999.2 [171], Tn1999.3 [186]
and Tn1999.4 [187]. Tn1999.4 is a mosaic of Tn1999 and a
second transposon, Tn2015, which additionally carries
blaCTX-M-15 [187]. In contrast to other CPE genes, dissemi-
nation of blaOXA-48 is associated with a single, successful
IncL/M plasmid into which the Tn1999 transposon has
inserted [173, 174, 178, 185, 187–193].
A variant of blaOXA-48, blaOXA-181, has also begun to dissem-
inate among Enterobacteriaceae and appears to be establish-
ing in the Indian subcontinent, South Africa and Singapore,
or in patients epidemiologically linked to these areas [194–
199]. Recently, the first cases of likely patient-to-patient
transmission have also been reported [200, 201]. blaOXA-181
has been identified on a non-self-conjugative ColE2 plasmid
in association with ISEcp1 and the Tn2013 transposon
[198]. Additionally, blaOXA-181 has been identified in the
same strains as blaNDM genes, reflecting its prevalence in
India [201, 202], and now in a conjugative plasmid [202],
suggesting widespread dissemination may occur in the
future.
THE CONTINUED THREAT OF AMR
The impact of antibiotic consumption is reflected in geo-
graphical variations of CPE and ESBL-E prevalence. Coun-
tries with high antibiotic consumption rates, such as
Fig. 1. Composite figure demonstrating the prevalence and characteristics of carbapenem resistance in Europe. (a) Percentage of
invasive isolates resistant to carbapenem antibiotics as determined by the European Centre for Disease Prevention and Control in the
Antimicrobial Resistance Surveillance in Europe 2015 report [11]. Each country is coloured according to the percentage of submitted
K. pneumoniae isolates that were non-susceptible to doripenem, imipenem or meropenem. (b) Pie charts indicating the distribution of
carbapenem-resistance mechanisms in K. pneumoniae isolates submitted to the EuSCAPE study [52]. Mechanisms are coloured
according to the key. ‘Other’ mechanisms: no KPC, NDM, OXA-48 or VIM genes detected. (c) Overall number of K. pneumoniae isolates
submitted by each participating country in the EuSCAPE study.
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Turkey, Tunisia, Algeria, Greece and Romania [71], have
particularly high rates of multidrug-resistant (MDR) bacter-
ia [11, 147]. Overuse of particular antibiotic classes also
affects MDR organisms, such as in Greece where high ceph-
alosporin use [203] is paralleled by high levels of ESBL-E
[11]. Travel to endemic regions also may be having a global
impact following acquisition of MDR pathogens by travel-
lers [204–208].
A particularly concerning issue, especially in Asia, is trans-
ferable colistin resistance [209]. Increased carbapenem
resistance has resulted in an increase in the use of polymyx-
ins (e.g. colistin) to treat XDR pathogens [71, 210]. We are
now faced with the dissemination of genes conferring resis-
tance to these drugs, which are frequently co-located with
additional resistance genes, leaving some infections almost
untreatable [211–214]. Following the first publication of the
transferrable colistin-resistance gene, mcr-1 [209], screening
has demonstrated global existence of mcr-1 in food, animal
and human samples [215, 216]. Following the association of
mcr-1 with ISApl-1 of the IS30 family and formation of the
composite transposon Tn6330, mcr-1 and its genetic envi-
ronment has stabilized [217–219]. It is now beginning to
spread across multiple plasmid types [214, 220–224]. The
ancestral mobilizable state of mcr-1 is more frequently iden-
tified in agricultural isolates than human isolates, particu-
larly those in China, supporting the theory of an animal
origin [209, 225–227]. Colistin is ubiquitous in food-animal
production [228], but its use as a growth promoter has been
banned in the European Union since 2006 and in China
since 2016 [229, 230]. This may begin to ease the antibiotic
selection pressure; however, it is difficult to speculate how
this may affect the human situation as stabilization and dis-
semination of the gene into conjugative plasmids has
already occurred.
CONCLUSION
Antimicrobial stewardship as a strategy to reduce AMR is
high on policy agendas in many countries [231–235] and a
positive impact on the prevalence of MDR pathogens is
beginning to show [236, 237]. Continued strategy develop-
ment is still required; accepted international definitions and
guidelines are yet to be adopted, particularly those suitable
for low-to-middle income countries [238]. With the incep-
tion of the ‘One Health’ initiative [233, 239, 240], consider-
ation should also be given to antimicrobial prescription in
primary care [30, 210, 241, 242], poorly regulated commu-
nity antimicrobial use [243–246] and agricultural antimi-
crobial use [239, 247–249].
The ability of CPE and ESBL-E to evolve and adapt rapidly
due to antibiotic selective pressures is one of the biggest
threats to medical care. An international, multi-disciplinary
approach is urgently required to tackle this global threat.
Pressing issues include improving surveillance to recognize
the importance of mobile AMR elements and increasing the
drive to move rapid, high-resolution diagnostics, such as
WGS, from the research environment into routine clinical
practice. A proactive approach involving all users of antimi-
crobials is imperative to prevent a return to the pre-
antibiotic era.
Funding information
This work was supported by the Academy of Medical Sciences, the
Health Foundation, and by the NIHR Cambridge Biomedical Research
Centre.
Acknowledgements
M. E. T. is a Clinician Scientist Fellow funded by the Academy of
Medical Sciences, the Health Foundation, and supported by the NIHR
Cambridge Biomedical Research Centre.
Conflicts of interest
The authors declare that there are no conflicts of interest.
References
1. Ray S, Anand D, Purwar S, Samanta A, Upadhye KV et al. Asso-
ciation of high mortality with extended-spectrum b-lactamase
(ESBL) positive cultures in community acquired infections. J Crit
Care 2018;44:255–260.
2. Schwaber MJ, Carmeli Y. Mortality and delay in effective ther-
apy associated with extended-spectrum b-lactamase production
in Enterobacteriaceae bacteraemia: a systematic review and
meta-analysis. J Antimicrob Chemother 2007;60:913–920.
3. Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on
Antibiotic Resistance. Clinical and economic impact of common
multidrug-resistant Gram-negative bacilli. Antimicrob Agents
Chemother 2008;52:813–821.
4. Tumbarello M, Spanu T, di Bidino R, Marchetti M, Ruggeri M
et al. Costs of bloodstream infections caused by Escherichia coli
and influence of extended-spectrum-b-lactamase production
and inadequate initial antibiotic therapy. Antimicrob Agents
Chemother 2010;54:4085–4091.
5. Melzer M, Petersen I. Mortality following bacteraemic infection
caused by extended spectrum b-lactamase (ESBL) producing
E. coli compared to non-ESBL producing E. coli. J Infect 2007;55:
254–259.
6. Fraenkel-Wandel Y, Raveh-Brawer D, Wiener-Well Y, Yinnon
AM, Assous MV. Mortality due to blaKPC Klebsiella pneumoniae
bacteraemia. J Antimicrob Chemother 2016;71:1083–1087.
7. Mcconville TH, Sullivan SB, Gomez-Simmonds A, Whittier S,
Uhlemann AC. Carbapenem-resistant Enterobacteriaceae coloni-
zation (CRE) and subsequent risk of infection and 90-day mor-
tality in critically ill patients, an observational study. PLoS One
2017;12:e0186195.
8. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mor-
tality of patients infected with carbapenem-resistant Klebsiella
pneumoniae. Ann Clin Microbiol Antimicrob 2017;16:18.
9. O’Neill J. The Review on Antimicrobial Resistance. London: Well-
come Trust and HM Government; 2016.
10. World Health Organization. Antimicrobial Resistance: Global
Report on Surveillance. Geneva: World Health Organization;
2014.
11. European Centre for Disease Prevention and Control.
Antimicrobial Resistance Surveillance in Europe 2015. Annual
Report of the European Antimicrobial Resistance Surveillance
Network (EARS-Net). Stockholm: European Centre for Disease
Prevention and Control; 2017.
12. World Health Organization. Global Priority List of Antibiotic-
Resistant Bacteria to Guide Research, Discovery, and Development
of New Antibiotics. Geneva: World Health Organization; 2017.
13. Drees M, Pineles L, Harris AD, Morgan DJ. Variation in defini-
tions and isolation procedures for multidrug-resistant
Gram-negative bacteria: a survey of the society for healthcare
epidemiology of america research network. Infect Control Hosp
Epidemiol 2014;35:362–366.
Wilson and Török, Microbial Genomics 2018;4
Downloaded from www.microbiologyresearch.org by
IP:  81.96.234.119
On: Wed, 01 Aug 2018 09:31:09
14. Paterson DL, Bonomo RA. Extended-spectrum b-lactamases: a
clinical update. Clin Microbiol Rev 2005;18:657–686.
15. Ambler RP. The structure of b-lactamases. Philos Trans R Soc
Lond B Biol Sci 1980;289:321–331.
16. Bush K, Jacoby GA. Updated functional classification of b-lacta-
mases. Antimicrob Agents Chemother 2010;54:969–976.
17. Decousser JW, Poirel L, Nordmann P. Characterization of a
chromosomally encoded extended-spectrum class A b-lacta-
mase from Kluyvera cryocrescens. Antimicrob Agents Chemother
2001;45:3595–3598.
18. Humeniuk C, Arlet G, Gautier V, Grimont P, Labia R et al. b-lac-
tamases of Kluyvera ascorbata, probable progenitors of some
plasmid-encoded CTX-M types. Antimicrob Agents Chemother
2002;46:3045–3049.
19. Poirel L, K€ampfer P, Nordmann P. Chromosome-encoded
Ambler class A b-lactamase of Kluyvera georgiana, a probable
progenitor of a subgroup of CTX-M extended-spectrum b-lacta-
mases. Antimicrob Agents Chemother 2002;46:4038–4040.
20. Naseer U, Sundsfjord A. The CTX-M conundrum: dissemination
of plasmids and Escherichia coli clones. Microb Drug Resist
2011;17:83–97.
21. Bauernfeind A, Schweighart S, Grimm H. A new plasmidic cefo-
taximase in a clinical isolate of Escherichia coli. Infection 1990;
18:294–298.
22. Bauernfeind A, Casellas JM, Goldberg M, Holley M, Jungwirth R
et al. A new plasmidic cefotaximase from patients infected with
Salmonella typhimurium. Infection 1992;20:158–163.
23. Ishii Y, Ohno A, Taguchi H, Imajo S, Ishiguro M et al. Cloning
and sequence of the gene encoding a cefotaxime-hydrolyzing
class A b-lactamase isolated from Escherichia coli. Antimicrob
Agents Chemother 1995;39:2269–2275.
24. Cantón R, Gonzalez-Alba JM, Galan JC. CTX-M enzymes: origin
and diffusion. Front Microbiol 2012;3:110.
25. Robin F, Beyrouthy R, Bonacorsi S, Aissa N, Bret L et al. Inven-
tory of extended-spectrum-b-lactamase-producing Enterobac-
teriaceae in France as assessed by a multicenter study.
Antimicrob Agents Chemother 2017;61:e01911-16.
26. Rios E, Lopez MC, Rodriguez-Avial I, Culebras E, Picazo JJ.
Detection of Escherichia coli ST131 clonal complex (ST705) and
Klebsiella pneumoniae ST15 among faecal carriage of extended-
spectrum b-lactamase- and carbapenemase-producing Entero-
bacteriaceae. J Med Microbiol 2017;66:169–174.
27. Pietsch M, Eller C, Wendt C, Holfelder M, Falgenhauer L et al.
Molecular characterisation of extended-spectrum b-lactamase
(ESBL)-producing Escherichia coli isolates from hospital and
ambulatory patients in Germany. Vet Microbiol 2017;200:130–
137.
28. Burke L, Humphreys H, Fitzgerald-Hughes D. The molecular
epidemiology of resistance in cefotaximase-producing Escheric-
hia coli clinical isolates from Dublin, Ireland. Microb Drug Resist
2016;22:552–558.
29. Willemsen I, Oome S, Verhulst C, Pettersson A, Verduin K et al.
Trends in extended spectrum b-lactamase (ESBL) producing
Enterobacteriaceae and ESBL genes in a Dutch teaching hospital,
measured in 5 yearly point prevalence surveys (2010–2014).
PLoS One 2015;10:e0141765.
30. Public Health England. English Surveillance Programme for
Antimicrobial Utilisation and Resistance (ESPAUR) Report 2017.
London: Public Health England; 2017.
31. Runcharoen C, Raven KE, Reuter S, Kallonen T, Paksanont S
et al. Whole genome sequencing of ESBL-producing Escherichia
coli isolated from patients, farm waste and canals in Thailand.
Genome Med 2017;9:81.
32. Lee MY, Ko KS, Kang CI, Chung DR, Peck KR et al. High preva-
lence of CTX-M-15-producing Klebsiella pneumoniae isolates in
Asian countries: diverse clones and clonal dissemination. Int J
Antimicrob Agents 2011;38:160–163.
33. Musicha P, Feasey NA, Cain AK, Kallonen T, Chaguza C et al.
Genomic landscape of extended-spectrum b-lactamase resis-
tance in Escherichia coli from an urban African setting. J
Antimicrob Chemother 2017;72:1602–1609.
34. Dziri R, Klibi N, Alonso CA, Said LB, Bellaaj R et al. Characteri-
zation of extended-spectrum b-lactamase (ESBL)-producing
Klebsiella, Enterobacter, and Citrobacter obtained in environmen-
tal samples of a Tunisian hospital. Diagn Microbiol Infect Dis
2016;86:190–193.
35. Eibach D, Belmar Campos C, Krumkamp R, Al-Emran HM,
Dekker D et al. Extended spectrum b-lactamase producing
Enterobacteriaceae causing bloodstream infections in rural
Ghana, 2007–2012. Int J Med Microbiol 2016;306:249–254.
36. Johnson JR, Johnston B, Clabots C, Kuskowski MA,
Castanheira M. Escherichia coli sequence type ST131 as the
major cause of serious multidrug-resistant E. coli infections in
the United States. Clin Infect Dis 2010;51:286–294.
37. Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A et al.
Community-associated extended-spectrum b-lactamase-
producing Escherichia coli infection in the United States. Clin
Infect Dis 2013;56:641–648.
38. Kim S, Sung JY, Cho HH, Kwon KC, Koo SH. Characteristics of
the molecular epidemiology of CTX-M-producing Escherichia coli
isolated from a tertiary hospital in Daejeon, Korea. J Microbiol
Biotechnol 2016;26:1643–1649.
39. Pallecchi L, Bartoloni A, Fiorelli C, Mantella A, di Maggio T et al.
Rapid dissemination and diversity of CTX-M extended-spectrum
b-lactamase genes in commensal Escherichia coli isolates from
healthy children from low-resource settings in Latin America.
Antimicrob Agents Chemother 2007;51:2720–2725.
40. Munday CJ, Xiong J, Li C, Shen D, Hawkey PM. Dissemination of
CTX-M type b-lactamases in Enterobacteriaceae isolates in the
People’s Republic of China. Int J Antimicrob Agents 2004;23:175–
180.
41. Liu W, Chen L, Li H, Duan H, Zhang Y et al. Novel CTX-M b-lacta-
mase genotype distribution and spread into multiple species of
Enterobacteriaceae in Changsha, Southern China. J Antimicrob
Chemother 2009;63:895–900.
42. Zhang J, Zheng B, Zhao L, Wei Z, Ji J et al. Nationwide high
prevalence of CTX-M and an increase of CTX-M-55 in Escherichia
coli isolated from patients with community-onset infections in
Chinese county hospitals. BMC Infect Dis 2014;14:659.
43. Zhong YM, Liu WE, Liang XH, Li YM, Jian ZJ et al. Emergence
and spread of O16-ST131 and O25b-ST131 clones among faecal
CTX-M-producing Escherichia coli in healthy individuals in Hunan
Province, China. J Antimicrob Chemother 2015;70:2223–2227.
44. Quan J, Zhao D, Liu L, Chen Y, Zhou J et al. High prevalence of
ESBL-producing Escherichia coli and Klebsiella pneumoniae in
community-onset bloodstream infections in China. J Antimicrob
Chemother 2017;72:273–280.
45. Li B, Lu Y, Lan F, He Q, Li C et al. Prevalence and characteristics
of ST131 clone among unselected clinical Escherichia coli in a
Chinese university hospital. Antimicrob Resist Infect Control
2017;6:118.
46. Chen LF, Freeman JT, Nicholson B, Keiger A, Lancaster S et al.
Widespread dissemination of CTX-M-15 genotype extended-
spectrum-b-lactamase-producing Enterobacteriaceae among
patients presenting to community hospitals in the southeastern
United States. Antimicrob Agents Chemother 2014;58:1200–1202.
47. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R,
Alonso MP et al. Intercontinental emergence of Escherichia coli
clone O25:H4-ST131 producing CTX-M-15. J Antimicrob
Chemother 2008;61:273–281.
48. Alghoribi MF, Gibreel TM, Farnham G, Al Johani SM, Balkhy HH
et al. Antibiotic-resistant ST38, ST131 and ST405 strains are
the leading uropathogenic Escherichia coli clones in Riyadh,
Saudi Arabia. J Antimicrob Chemother 2015;70:2757–2762.
Wilson and Török, Microbial Genomics 2018;4
7
Downloaded from www.microbiologyresearch.org by
IP:  81.96.234.119
On: Wed, 01 Aug 2018 09:31:09
49. Peirano G, van der Bij AK, Gregson DB, Pitout JD. Molecular
epidemiology over an 11-year period (2000 to 2010) of
extended-spectrum b-lactamase-producing Escherichia coli
causing bacteremia in a centralized Canadian region. J Clin
Microbiol 2012;50:294–299.
50. Oteo J, Cuevas O, Lopez-Rodriguez I, Banderas-Florido A,
Vindel A et al. Emergence of CTX-M-15-producing Klebsiella
pneumoniae of multilocus sequence types 1, 11, 14, 17, 20, 35
and 36 as pathogens and colonizers in newborns and adults.
J Antimicrob Chemother 2009;64:524–528.
51. Ks K, Lee JY, Baek JY, Suh JY, Lee MY et al. Predominance of
an ST11 extended-spectrum b-lactamase-producing Klebsiella
pneumoniae clone causing bacteraemia and urinary tract infec-
tions in Korea. J Med Microbiol 2010;59:822–828.
52. Coque TM, Novais A, Carattoli A, Poirel L, Pitout J et al. Dissem-
ination of clonally related Escherichia coli strains expressing
extended-spectrum b-lactamase CTX-M-15. Emerg Infect Dis
2008;14:195–200.
53. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-
ST131: a pandemic, multiresistant, community-associated
strain. J Antimicrob Chemother 2011;66:1–14.
54. Ben Zakour NL, Alsheikh-Hussain AS, Ashcroft MM, Khanh Nhu
NT, Roberts LW et al. Sequential acquisition of virulence and
fluoroquinolone resistance has shaped the evolution of Escheric-
hia coli ST131. mBio 2016;7.
55. Petty NK, Ben Zakour NL, Stanton-Cook M, Skippington E,
Totsika M et al. Global dissemination of a multidrug resistant
Escherichia coli clone. Proc Natl Acad Sci USA 2014;111:5694–
5699.
56. Price LB, Johnson JR, Aziz M, Clabots C, Johnston B et al. The
epidemic of extended-spectrum-b-lactamase-producing
Escherichia coli ST131 is driven by a single highly pathogenic
subclone, H30-Rx. MBio 2013;4:e00377-13.
57. Schembri MA, Zakour NL, Phan MD, Forde BM, Stanton-Cook M
et al. Molecular characterization of the multidrug resistant
Escherichia coli ST131 clone. Pathogens 2015;4:422–430.
58. Peirano G, van der Bij AK, Freeman JL, Poirel L, Nordmann P
et al. Characteristics of Escherichia coli sequence type 131 iso-
lates that produce extended-spectrum b-lactamases: global dis-
tribution of the H30-Rx sublineage. Antimicrob Agents Chemother
2014;58:3762–3767.
59. Stoesser N, Sheppard AE, Pankhurst L, De Maio N, Moore CE
et al. Evolutionary history of the global emergence of the
Escherichia coli epidemic clone ST131. MBio 2016;7:e02162-15.
60. Paul S, Linardopoulou EV, Billig M, Tchesnokova V, Price LB
et al. Role of homologous recombination in adaptive diversifica-
tion of extraintestinal Escherichia coli. J Bacteriol 2013;195:231–
242.
61. Ciesielczuk H, Doumith M, Hope R, Woodford N, Wareham DW.
Characterization of the extra-intestinal pathogenic Escherichia
coli ST131 clone among isolates recovered from urinary and
bloodstream infections in the United Kingdom. J Med Microbiol
2015;64:1496–1503.
62. Day MJ, Rodríguez I, van Essen-Zandbergen A, Dierikx C,
Kadlec K et al. Diversity of STs, plasmids and ESBL genes
among Escherichia coli from humans, animals and food in Ger-
many, the Netherlands and the UK. J Antimicrob Chemother
2016;71:1178–1182.
63. Doumith M, Dhanji H, Ellington MJ, Hawkey P, Woodford N.
Characterization of plasmids encoding extended-spectrum b-
lactamases and their addiction systems circulating among
Escherichia coli clinical isolates in the UK. J Antimicrob
Chemother 2012;67:878–885.
64. Chen L, Hu H, Chavda KD, Zhao S, Liu R et al. Complete
sequence of a KPC-producing IncN multidrug-resistant plasmid
from an epidemic Escherichia coli sequence type 131 strain in
China. Antimicrob Agents Chemother 2014;58:2422–2425.
65. Partridge SR, Ellem JA, Tetu SG, Zong Z, Paulsen IT et al. Com-
plete sequence of pJIE143, a pir-type plasmid carrying ISEcp1-
blaCTX-M-15 from an Escherichia coli ST131 isolate. Antimicrob
Agents Chemother 2011;55:5933–5935.
66. Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ
et al. Complete nucleotide sequences of plasmids pEK204,
pEK499, and pEK516, encoding CTX-M enzymes in three major
Escherichia coli lineages from the United Kingdom, all belonging
to the international O25:H4-ST131 clone. Antimicrob Agents
Chemother 2009;53:4472–4482.
67. Osborn AM, da Silva Tatley FM, Steyn LM, Pickup RW,
Saunders JR. Mosaic plasmids and mosaic replicons: evolution-
ary lessons from the analysis of genetic diversity in IncFII-
related replicons. Microbiology 2000;146:2267–2275.
68. Villa L, García-Fernandez A, Fortini D, Carattoli A. Replicon
sequence typing of IncF plasmids carrying virulence and resis-
tance determinants. J Antimicrob Chemother 2010;65:2518–
2529.
69. Phan MD, Forde BM, Peters KM, Sarkar S, Hancock S et al.
Molecular characterization of a multidrug resistance IncF plas-
mid from the globally disseminated Escherichia coli ST131
clone. PLoS One 2015;10:e0122369.
70. McNally A, Oren Y, Kelly D, Pascoe B, Dunn S et al. Combined
analysis of variation in core, accessory and regulatory genome
regions provides a super-resolution view into the evolution of
bacterial populations. PLoS Genet 2016;12:e1006280.
71. Klein EY, van Boeckel TP, Martinez EM, Pant S, Gandra S et al.
Global increase and geographic convergence in antibiotic con-
sumption between 2000 and 2015. Proc Natl Acad Sci USA 2018;
115:E3463–E3470.
72. Meyer E, Schwab F, Schroeren-Boersch B, Gastmeier P. Dra-
matic increase of third-generation cephalosporin-resistant
E. coli in German intensive care units: secular trends in antibi-
otic drug use and bacterial resistance, 2001 to 2008. Crit Care
2010;14:R113.
73. McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M et al.
Correlations of antibiotic use and carbapenem resistance in
Enterobacteriaceae. Antimicrob Agents Chemother 2013;57:5131–
5133.
74. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in
Enterobacteriaceae: here is the storm!. Trends Mol Med 2012;18:
263–272.
75. Logan LK, Weinstein RA. The epidemiology of carbapenem-
resistant Enterobacteriaceae: the impact and evolution of a
global menace. J Infect Dis 2017;215S28–S36.
76. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A,
Biddle JW et al. Novel carbapenem-hydrolyzing b-lactamase,
KPC-1, from a carbapenem-resistant strain of Klebsiella pneu-
moniae. Antimicrob Agents Chemother 2001;45:1151–1161.
77. Tavares CP, Pereira PS, Marques EA, Faria C, de Souza MP
et al. Molecular epidemiology of KPC-2-producing Enterobacter-
iaceae (non-Klebsiella pneumoniae) isolated from Brazil. Diagn
Microbiol Infect Dis 2015;82:326–330.
78. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N et al. Emer-
gence of carbapenem-resistant Klebsiella species possessing
the class A carbapenem-hydrolyzing KPC-2 and inhibitor-
resistant TEM-30 b-lactamases in New York City. Clin Infect Dis
2004;39:55–60.
79. Castanheira M, Costello AJ, Deshpande LM, Jones RN. Expan-
sion of clonal complex 258 KPC-2-producing Klebsiella pneumo-
niae in Latin American hospitals: report of the SENTRY
antimicrobial surveillance program. Antimicrob Agents
Chemother 2012;56:1668–1669.
80. Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones
RN. Prevalence of b-lactamase-encoding genes among Entero-
bacteriaceae bacteremia isolates collected in 26 U.S. hospitals:
report from the SENTRY antimicrobial surveillance program
(2010). Antimicrob Agents Chemother 2013;57:3012–3020.
Wilson and Török, Microbial Genomics 2018;4
8
Downloaded from www.microbiologyresearch.org by
IP:  81.96.234.119
On: Wed, 01 Aug 2018 09:31:09
81. Chiang T, Mariano N, Urban C, Colon-Urban R, Grenner L et al.
Identification of carbapenem-resistant Klebsiella pneumoniae
harboring KPC enzymes in New Jersey. Microb Drug Resist
2007;13:235–240.
82. Giakkoupi P, Papagiannitsis CC, Miriagou V, Pappa O, Polemis
M et al. An update of the evolving epidemic of blaKPC-2-carrying
Klebsiella pneumoniae in Greece (2009–10). J Antimicrob
Chemother 2011;66:1510–1513.
83. Richter SN, Frasson I, Franchin E, Bergo C, Lavezzo E et al.
KPC-mediated resistance in Klebsiella pneumoniae in two hospi-
tals in Padua, Italy, June 2009–December 2011: massive
spreading of a KPC-3-encoding plasmid and involvement of
non-intensive care units. Gut Pathog 2012;4:7.
84. Zhang R, Liu L, Zhou H, Chan EW, Li J et al. Nationwide surveil-
lance of clinical carbapenem-resistant Enterobacteriaceae (CRE)
strains in China. EBioMedicine 2017;19:98–106.
85. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S
et al. Molecular epidemiology of KPC-producing Klebsiella pneu-
moniae isolates in the United States: clonal expansion of multi-
locus sequence type 258. Antimicrob Agents Chemother 2009;53:
3365–3370.
86. Breurec S, Guessennd N, Timinouni M, Le TA, Cao V et al. Kleb-
siella pneumoniae resistant to third-generation cephalosporins
in five African and two Vietnamese major towns: multiclonal
population structure with two major international clonal groups,
CG15 and CG258. Clin Microbiol Infect 2013;19:349–355.
87. Chen L, Mathema B, Chavda KD, Deleo FR, Bonomo RA et al.
Carbapenemase-producing Klebsiella pneumoniae: molecular
and genetic decoding. Trends Microbiol 2014;22:686–696.
88. Tegmark-Wisell K, Haeggman S, Gezelius L, Thompson O,
Gustafsson I et al. Identification of Klebsiella pneumoniae carba-
penemase in Sweden. Euro Surveill 2007;12:3333.
89. Maltezou HC, Giakkoupi P, Maragos A, Bolikas M, Raftopoulos V
et al. Outbreak of infections due to KPC-2-producing Klebsiella
pneumoniae in a hospital in Crete (Greece). J Infect 2009;58:213–
219.
90. Pournaras S, Protonotariou E, Voulgari E, Kristo I, Dimitroulia E
et al. Clonal spread of KPC-2 carbapenemase-producing Klebsi-
ella pneumoniae strains in Greece. J Antimicrob Chemother 2009;
64:348–352.
91. Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou
G et al. An outbreak of infection due to b-lactamase Klebsiella
pneumoniae carbapenemase 2-producing K. pneumoniae in a
Greek University Hospital: molecular characterization, epidemi-
ology, and outcomes. Clin Infect Dis 2010;50:364–373.
92. Kontopoulou K, Protonotariou E, Vasilakos K, Kriti M, Koteli A
et al. Hospital outbreak caused by Klebsiella pneumoniae pro-
ducing KPC-2 b-lactamase resistant to colistin. J Hosp Infect
2010;76:70–73.
93. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M,
Giacobbe DR et al. Infections caused by KPC-producing Klebsi-
ella pneumoniae: differences in therapy and mortality in a multi-
centre study. J Antimicrob Chemother 2015;70:2133–2143.
94. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V
et al. Predictors of mortality in patients with bloodstream infec-
tions caused by KPC-producing Klebsiella pneumoniae and
impact of appropriate antimicrobial treatment. Clin Microbiol
Infect 2011;17:1798–1803.
95. Lübbert C, Becker-Rux D, Rodloff AC, Laudi S, Busch T et al.
Colonization of liver transplant recipients with KPC-producing
Klebsiella pneumoniae is associated with high infection rates
and excess mortality: a case-control analysis. Infection 2014;42:
309–316.
96. Bogaerts P, Montesinos I, Rodriguez-Villalobos H, Blairon L,
Deplano A et al. Emergence of clonally related Klebsiella pneu-
moniae isolates of sequence type 258 producing KPC-2 carbape-
nemase in Belgium. J Antimicrob Chemother 2010;65:361–362.
97. Chua KY, Grayson ML, Burgess AN, Lee JY, Howden BP. The
growing burden of multidrug-resistant infections among
returned Australian travellers. Med J Aust 2014;200:116–118.
98. Lopez JA, Correa A, Navon-Venezia S, Correa AL, Torres JA
et al. Intercontinental spread from Israel to Colombia of a KPC-
3-producing Klebsiella pneumoniae strain. Clin Microbiol Infect
2011;17:52–56.
99. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated car-
bapenem-hydrolyzing b-lactamase KPC in a Klebsiella pneumo-
niae isolate from France. Antimicrob Agents Chemother 2005;49:
4423–4424.
100. Samuelsen O, Naseer U, Tofteland S, Skutlaberg DH, Onken A
et al. Emergence of clonally related Klebsiella pneumoniae iso-
lates of sequence type 258 producing plasmid-mediated KPC
carbapenemase in Norway and Sweden. J Antimicrob Chemother
2009;63:654–658.
101. Wendt C, Schütt S, Dalpke AH, Konrad M, Mieth M et al. First
outbreak of Klebsiella pneumoniae carbapenemase (KPC)-pro-
ducing K. pneumoniae in Germany. Eur J Clin Microbiol Infect Dis
2010;29:563–570.
102. Kanerva M, Skogberg K, Ryyn€anen K, Pahkam€aki A, Jalava J
et al. Coincidental detection of the first outbreak of carbapene-
mase-producing Klebsiella pneumoniae colonisation in a primary
care hospital, Finland, 2013. Euro Surveill 2015;20:21172.
103. Kwong JC, Lane CR, Romanes F, Gonçalves da Silva A, Easton
M et al. Translating genomics into practice for real-time surveil-
lance and response to carbapenemase-producing Enterobacter-
iaceae: evidence from a complex multi-institutional KPC
outbreak. PeerJ 2018;6:e4210.
104. Chen S, Hu F, Xu X, Liu Y, Wu W et al. High prevalence of KPC-
2-type carbapenemase coupled with CTX-M-type extended-
spectrum b-lactamases in carbapenem-resistant Klebsiella
pneumoniae in a teaching hospital in China. Antimicrob Agents
Chemother 2011;55:2493–2494.
105. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos
GL et al. Clinical epidemiology of the global expansion of Klebsi-
ella pneumoniae carbapenemases. Lancet Infect Dis 2013;13:
785–796.
106. Qi Y, Wei Z, Ji S, Du X, Shen P et al. ST11, the dominant clone of
KPC-producing Klebsiella pneumoniae in China. J Antimicrob
Chemother 2011;66:307–312.
107. Stoesser N, Sheppard AE, Peirano G, Anson LW, Pankhurst L
et al. Genomic epidemiology of global Klebsiella pneumoniae car-
bapenemase (KPC)-producing Escherichia coli. Sci Rep 2017;7:
5917.
108. Cuzon G, Naas T, Nordmann P. Functional characterization of
Tn4401, a Tn3-based transposon involved in blaKPC gene mobili-
zation. Antimicrob Agents Chemother 2011;55:5370–5373.
109. Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP et al.
Genetic structures at the origin of acquisition of the b-lacta-
mase blaKPC gene. Antimicrob Agents Chemother 2008;52:1257–
1263.
110. Chen L, Chavda KD, Al Laham N, Melano RG, Jacobs MR et al.
Complete nucleotide sequence of a blaKPC-harboring IncI2 plas-
mid and its dissemination in New Jersey and New York hospi-
tals. Antimicrob Agents Chemother 2013;57:5019–5025.
111. Chmelnitsky I, Shklyar M, Leavitt A, Sadovsky E, Navon-Venezia
S et al. Mix and match of KPC-2 encoding plasmids in Entero-
bacteriaceae-comparative genomics. Diagn Microbiol Infect Dis
2014;79:255–260.
112. Andrade LN, Curiao T, Ferreira JC, Longo JM, Clímaco EC et al.
Dissemination of blaKPC-2 by the spread of Klebsiella pneumoniae
clonal complex 258 clones (ST258, ST11, ST437) and plasmids
(IncFII, IncN, IncL/M) among Enterobacteriaceae species in Brazil.
Antimicrob Agents Chemother 2011;55:3579–3583.
113. Ho PL, Cheung YY, Lo WU, Li Z, Chow KH et al. Molecular char-
acterization of an atypical IncX3 plasmid pKPC-NY79 carrying
Wilson and Török, Microbial Genomics 2018;4
9
Downloaded from www.microbiologyresearch.org by
IP:  81.96.234.119
On: Wed, 01 Aug 2018 09:31:09
blaKPC-2 in a Klebsiella pneumoniae. Curr Microbiol 2013;67:
493–498.
114. Cerqueira GC, Earl AM, Ernst CM, Grad YH, Dekker JP et al.
Multi-institute analysis of carbapenem resistance reveals
remarkable diversity, unexplained mechanisms, and limited
clonal outbreaks. Proc Natl Acad Sci USA 2017;114:1135–1140.
115. Esteban-Cantos A, Aracil B, Bautista V, Ortega A, Lara N et al.
The carbapenemase-producing Klebsiella pneumoniae popula-
tion is distinct and more clonal than the carbapenem-
susceptible population. Antimicrob Agents Chemother 2017;61:
e02520-16.
116. Gomez SA, Pasteran FG, Faccone D, Tijet N, Rapoport M et al.
Clonal dissemination of Klebsiella pneumoniae ST258 harbouring
KPC-2 in Argentina. Clin Microbiol Infect 2011;17:1520–1524.
117. Weterings V, Zhou K, Rossen JW, van Stenis D, Thewessen E
et al. An outbreak of colistin-resistant Klebsiella pneumoniae
carbapenemase-producing Klebsiella pneumoniae in the Nether-
lands (July to December 2013), with inter-institutional spread.
Eur J Clin Microbiol Infect Dis 2015;34:1647–1655.
118. Sheppard AE, Stoesser N, Wilson DJ, Sebra R, Kasarskis A
et al. Nested russian doll-like genetic mobility drives rapid dis-
semination of the carbapenem resistance gene blaKPC.
Antimicrob Agents Chemother 2016;60:3767–3778.
119. Kanamori HPC, Juliano JJ, van Duin D, Cairns BA, Weber DJ
et al. A prolonged outbreak of KPC-3-producing Enterobacter
cloacae and Klebsiella pneumoniae driven by multiple mecha-
nisms of resistance transmission at a large academic burn cen-
ter. Antimicrob Agents Chemother 2016;61:e01516-16.
120. Mathers AJ, Stoesser N, Sheppard AE, Pankhurst L, Giess A
et al. Klebsiella pneumoniae carbapenemase (KPC)-producing K.
pneumoniae at a single institution: insights into endemicity from
whole-genome sequencing. Antimicrob Agents Chemother 2015;
59:1656–1663.
121. Zong Z, Yu F, Connor C, Fenn S, McNally A. Complete genomic
characterisation of two Escherichia coli lineages responsible for
a cluster of carbapenem resistant infections in a Chinese hospi-
tal. bioRxiv 2018.
122. Pl H, Cheung YY, Wang Y, Wu L, Lai EL et al. Characterization of
carbapenem-resistant Escherichia coli and Klebsiella pneumoniae
from a healthcare region in Hong Kong. European J Clin
Microbiol Infect Dis 2016;35:379–385.
123. Chavda KD, Chen L, Jacobs MR, Bonomo RA, Kreiswirth BN.
Molecular diversity and plasmid analysis of KPC-producing
Escherichia coli. Antimicrob Agents Chemother 2016;60:4073–
4081.
124. Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE,
Biedenbach DJ et al. Multiyear, multinational survey of the inci-
dence and global distribution of metallo-b-lactamase-producing
Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob
Agents Chemother 2016;60:1067–1078.
125. Bathoorn E, Rossen JW, Lokate M, Friedrich AW, Hammerum
AM. Isolation of an NDM-5-producing ST16 Klebsiella pneumo-
niae from a Dutch patient without travel history abroad, August
2015. Euro Surveill 2015;20:30040.
126. Huang TW, Wang JT, Lauderdale TL, Liao TL, Lai JF et al. Com-
plete sequences of two plasmids in a blaNDM-1-positive Klebsiella
oxytoca isolate from Taiwan. Antimicrob Agents Chemother 2013;
57:4072–4076.
127. Stoesser N, Giess A, Batty EM, Sheppard AE, Walker AS et al.
Genome sequencing of an extended series of NDM-producing
Klebsiella pneumoniae isolates from neonatal infections in a
Nepali hospital characterizes the extent of community- versus
hospital-associated transmission in an endemic setting.
Antimicrob Agents Chemother 2014;58:7347–7357.
128. Wailan AM, Paterson DL, Kennedy K, Ingram PR, Bursle E et al.
Genomic characteristics of NDM-producing Enterobacteriaceae
isolates in Australia and their blaNDMgenetic contexts.
Antimicrob Agents Chemother 2016;60:136–141.
129. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K et al. Char-
acterization of a new metallo-b-lactamase gene, blaNDM-1, and a
novel erythromycin esterase gene carried on a unique genetic
structure in Klebsiella pneumoniae sequence type 14 from India.
Antimicrob Agents Chemother 2009;60:5046–5054.
130. Chihara S, Okuzumi K, Yamamoto Y, Oikawa S, Hishinuma A.
First case of New Delhi metallo-b-lactamase 1-producing
Escherichia coli infection in Japan. Clin Infect Dis 2011;52:153–
154.
131. Gaibani P, Ambretti S, Berlingeri A, Cordovana M, Farruggia P
et al. Outbreak of NDM-1-producing Enterobacteriaceae in north-
ern Italy, July to August 2011. Euro Surveill 2011;16:20027.
132. McDermott H, Morris D, McArdle E, O’Mahony G, Kelly S et al.
Isolation of NDM-1-producing Klebsiella pneumoniae in Ireland,
July 2011. Euro Surveill 2012;17:20087.
133. Nielsen JB, Hansen F, Littauer P, Schonning K, Hammerum
AM. An NDM-1-producing Escherichia coli obtained in Denmark
has a genetic profile similar to an NDM-1-producing E. coli iso-
late from the UK. J Antimicrob Chemother 2012;67:2049–2051.
134. Osterblad M, Kirveskari J, Hakanen AJ, Tissari P, Vaara M et al.
Carbapenemase-producing Enterobacteriaceae in Finland: the
first years (2008–11). J Antimicrob Chemother 2012;67:2860–
2864.
135. Oteo J, Domingo-Garcia D, Fernandez-Romero S, Saez D, Guiu
A et al. Abdominal abscess due to NDM-1-producing Klebsiella
pneumoniae in Spain. J Med Microbiol 2012;61:864–867.
136. Peirano G, Ahmed-Bentley J, Woodford N, Pitout JD. New Delhi
metallo-b-lactamase from traveler returning to Canada. Emerg
Infect Dis 2011;17:242–244.
137. Pfeifer Y, Witte W, Holfelder M, Busch J, Nordmann P et al.
NDM-1-producing Escherichia coli in Germany. Antimicrob Agents
Chemother 2011;55:1318–1319.
138. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. Emer-
gence of metallo-b-lactamase NDM-1-producing multidrug-
resistant Escherichia coli in Australia. Antimicrob Agents
Chemother 2010;54:4914–4916.
139. Samuelsen Ø, Thilesen CM, Heggelund L, Vada AN, Kümmel A
et al. Identification of NDM-1-producing Enterobacteriaceae in
Norway. J Antimicrob Chemother 2011;66:670–672.
140. Tijet N, Alexander DC, Richardson D, Lastovetska O, Low DE
et al. New Delhi metallo-beta-lactamase, Ontario, Canada.
Emerg Infect Dis 2011;17:306–307.
141. Williamson DA, Sidjabat HE, Freeman JT, Roberts SA, Silvey A
et al. Identification and molecular characterisation of New Delhi
metallo-b-lactamase-1 (NDM-1)- and NDM-6-producing Entero-
bacteriaceae from New Zealand hospitals. Int J Antimicrob
Agents 2012;39:529–533.
142. Wu HS, Chen T-L, Chen IC-J, Huang M-S, Wang F-D et al. First
identification of a patient colonized with Klebsiella pneumoniae
carrying blaNDM-1 in Taiwan. J Chin Med Assoc 2010;73:596–598.
143. Zarfel G, Hoenigl M, Leitner E, Salzer HJ, Feierl G et al. Emer-
gence of New Delhi metallo-b-lactamase, Austria. Emerg Infect
Dis 2011;17:129–130.
144. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F
et al. Emergence of a new antibiotic resistance mechanism in
India, Pakistan, and the UK: a molecular, biological, and epide-
miological study. Lancet Infect Dis 2010;10:597–602.
145. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination
of NDM-1 positive bacteria in the New Delhi environment and its
implications for human health: an environmental point preva-
lence study. Lancet Infect Dis 2011;11:355–362.
146. Dortet L, Poirel L, Nordmann P. Worldwide dissemination of the
NDM-type carbapenemases in Gram-negative bacteria. Biomed
Res Int 2014;2014:249856.
147. Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL
et al. Carbapenemase-producing Enterobacteriaceae in Europe:
assessment by national experts from 38 countries, May 2015.
Euro Surveill 2015;20:30062.
Wilson and Török, Microbial Genomics 2018;4
10
Downloaded from www.microbiologyresearch.org by
IP:  81.96.234.119
On: Wed, 01 Aug 2018 09:31:09
148. Phan HTT, Stoesser N, Maciuca IE, Toma F, Szekely E et al. Illu-
mina short-read and MinION long-read WGS to characterize the
molecular epidemiology of an NDM-1 Serratia marcescens out-
break in Romania. J Antimicrob Chemother 2018;73:672–679.
149. Bosch T, Lutgens SPM, Hermans MHA, Wever PC,
Schneeberger PM et al. Outbreak of NDM-1-producing Klebsiella
pneumoniae in a Dutch hospital, with interspecies transfer of the
resistance plasmid and unexpected occurrence in unrelated
health care centers. J Clin Microbiol 2017;55:2380–2390.
150. Nordmann P, Poirel L. The difficult-to-control spread of carba-
penemase producers among Enterobacteriaceae worldwide. Clin
Microbiol Infect 2014;20:821–830.
151. Sekizuka T, Matsui M, Yamane K, Takeuchi F, Ohnishi M et al.
Complete sequencing of the blaNDM-1-positive IncA/C plasmid
from Escherichia coli ST38 isolate suggests a possible origin
from plant pathogens. PLoS One 2011;6:e25334.
152. Villa L, Poirel L, Nordmann P, Carta C, Carattoli A. Complete
sequencing of an IncH plasmid carrying the blaNDM-1, blaCTX-M-15
and qnrB1 genes. J Antimicrob Chemother 2012;67:1645–1650.
153. Wailan AM, Sartor AL, Zowawi HM, Perry JD, Paterson DL et al.
Genetic contexts of blaNDM-1 in patients carrying multiple NDM-
producing strains. Antimicrob Agents Chemother 2015;59:7405–
7410.
154. Giske CG, Fröding I, Hasan CM, Turlej-Rogacka A, Toleman M
et al. Diverse sequence types of Klebsiella pneumoniae contrib-
ute to the dissemination of blaNDM-1 in India, Sweden, and the
United Kingdom. Antimicrob Agents Chemother 2012;56:2735–
2738.
155. Khong WX, Xia E, Marimuthu K, Xu W, Teo YY et al. Local trans-
mission and global dissemination of New Delhi metallo-b-lacta-
mase (NDM): a whole genome analysis. BMC Genomics 2016;17:
452.
156. Wailan AM, Sidjabat HE, Yam WK, Alikhan NF, Petty NK et al.
Mechanisms involved in acquisition of blaNDM genes by IncA/C2
and IncFIIY plasmids. Antimicrob Agents Chemother 2016;60:
4082–4088.
157. Toleman MA, Spencer J, Jones L, Walsh TR. blaNDM-1 is a chi-
mera likely constructed in Acinetobacter baumannii. Antimicrob
Agents Chemother 2012;56:2773–2776.
158. Lauretti L, Riccio M, Mazzariol A, Cornaglia G, Amicosante G
et al. Cloning and characterization of blaVIM, a new integron-
borne metallo-b-lactamase gene from a Pseudomonas aerugi-
nosa clinical isolate. Antimicrob Agents Chemother 1999;43:
1584–1590.
159. Matsumura Y, Peirano G, Devinney R, Bradford PA, Motyl MR
et al. Genomic epidemiology of global VIM-producing Enterobac-
teriaceae. J Antimicrob Chemother 2017;72:2249–2258.
160. Esposito EP, Gaiarsa S, Del Franco M, Crivaro V, Bernardo M
et al. A novel IncA/C1 group conjugative plasmid, encoding VIM-
1 metallo-b-lactamase, mediates the acquisition of carbapenem
resistance in ST104 Klebsiella pneumoniae isolates from neo-
nates in the intensive care unit of V. Monaldi Hospital in Naples.
Front Microbiol 2017;8:2135.
161. Papagiannitsis CC, Izdebski R, Baraniak A, Fiett J, Herda M
et al. Survey of metallo-b-lactamase-producing Enterobacteria-
ceae colonizing patients in European ICUs and rehabilitation
units, 2008–11. J Antimicrob Chemother 2015;70:1981–1988.
162. Ito H, Arakawa Y, Ohsuka S, Wacharotayankun R, Kato N et al.
Plasmid-mediated dissemination of the metallo-b-lactamase
gene blaIMP among clinically isolated strains of Serratia marces-
cens. Antimicrob Agents Chemother 1995;39:824–829.
163. Sidjabat HE, Townell N, Nimmo GR, George NM, Robson J et al.
Dominance of IMP-4-producing Enterobacter cloacae among car-
bapenemase-producing Enterobacteriaceae in Australia.
Antimicrob Agents Chemother 2015;59:4059–4066.
164. Matsumura Y, Peirano G, Motyl MR, Adams MD, Chen L et al.
Global molecular epidemiology of IMP-producing Enterobacteria-
ceae. Antimicrob Agents Chemother 2017;61:e02729-16.
165. Yamazaki Y, Funaki T, Yasuhara T, Sugano E, Ugajin K et al.
Molecular characteristics of a carbapenemase-producing Enter-
obacter species and Klebsiella species outbreak in a Japanese
University Hospital. Showa Univer J Med Sciences 2017;29:163–
172.
166. Yamamoto N, Asada R, Kawahara R, Hagiya H, Akeda Y et al.
Prevalence of, and risk factors for, carriage of carbapenem-
resistant Enterobacteriaceae among hospitalized patients in
Japan. J Hosp Infect 2017;97:212–217.
167. Peleg AY, Franklin C, Bell JM, Spelman DW. Dissemination of
the metallo-b-lactamase gene blaIMP-4 among Gram-negative
pathogens in a clinical setting in Australia. Clin Infect Dis 2005;
2005:1549–1556.
168. Sidjabat HE, Robson J, Paterson DL. Draft genome sequences
of two IMP-4-producing Escherichia coli sequence type 131 iso-
lates in Australia. Genome Announc 2015;3:e00983-15.
169. Stoesser N, Sheppard AE, Peirano G, Sebra RP, Lynch T et al.
First report of blaIMP-14 on a plasmid harboring multiple drug
resistance genes in Escherichia coli sequence type 131.
Antimicrob Agents Chemother 2016;60:5068–5071.
170. Aktas Z, Kayacan CB, Schneider I, Can B, Midilli K et al. Carba-
penem-hydrolyzing oxacillinase, OXA-48, persists in Klebsiella
pneumoniae in Istanbul, Turkey. Chemotherapy 2008;54:101–106.
171. Carr€er A, Poirel L, Eraksoy H, Cagatay AA, Badur S et al.
Spread of OXA-48-positive carbapenem-resistant Klebsiella
pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents
Chemother 2008;52:2950–2954.
172. Poirel L, Heritier C, Tolün V, Nordmann P. Emergence of oxacil-
linase-mediated resistance to imipenem in Klebsiella pneumo-
niae. Antimicrob Agents Chemother 2004;48:15–22.
173. Mataseje LF, Boyd DA, Fuller J, Haldane D, Hoang L et al. Char-
acterization of OXA-48-like carbapenemase producers in Can-
ada, 2011–14. J Antimicrob Chemother 2018;73:626–633.
174. Potron A, Poirel L, Rondinaud E, Nordmann P. Intercontinental
spread of OXA-48 b-lactamase-producing Enterobacteriaceae
over a 11-year period, 2001 to 2011. Euro Surveill 2013;18:
20549.
175. Potron A, Kalpoe J, Poirel L, Nordmann P. European dissemina-
tion of a single OXA-48-producing Klebsiella pneumoniae clone.
Clin Microbiol Infect 2011;17:E24–E26.
176. Kilic A, Aktas Z, Bedir O, Gumral R, Bulut Y et al. Identification
and characterization of OXA-48 producing, carbapenem-
resistant Enterobacteriaceae isolates in Turkey. Ann Clin Lab Sci
2011;41:161–166.
177. Moubareck CA, Mouftah SF, Pal T, Ghazawi A, Halat DH et al.
Clonal emergence of Klebsiella pneumoniae ST14 co-producing
OXA-48-type and NDM carbapenemases with high rate of colis-
tin resistance in Dubai, United Arab Emirates. Int J Antimicrob
Agents 2018;52:90–95.
178. Solgi H, Giske CG, Badmasti F, Aghamohammad S, Havaei SA
et al. Emergence of carbapenem resistant Escherichia coli iso-
lates producing blaNDM and blaOXA-48-like carried on IncA/C and
IncL/M plasmids at two Iranian university hospitals. Infect Genet
Evol 2017;55:318–323.
179. Loucif L, Chelaghma W, Helis Y, Sebaa F, Baoune RD et al. First
detection of OXA-48-producing Klebsiella pneumoniae in commu-
nity-acquired urinary tract infection in Algeria. J Glob Antimicrob
Resist 2018;12:115–116.
180. Jhang J, Wang HY, Yoo G, Hwang GY, Uh Y et al. NDM-5 and
OXA-48 co-producing uropathogenic Escherichia coli isolate: first
case in Korea. Ann Lab Med 2018;38:277–279.
181. Poirel L, Heritier C, Nordmann P. Chromosome-encoded ambler
class D b-lactamase of Shewanella oneidensis as a progenitor of
carbapenem-hydrolyzing oxacillinase. Antimicrob Agents
Chemother 2004;48:348–351.
182. Lyman M, Walter M, Lonsway D, Rasheed K, Limbago B et al.
Notes from the field: carbapenem-resistant Enterobacteriaceae
Wilson and Török, Microbial Genomics 2018;4
11
Downloaded from www.microbiologyresearch.org by
IP:  81.96.234.119
On: Wed, 01 Aug 2018 09:31:09
producing OXA-48-like carbapenemases – United States, 2010–
2015. MMWR 2015;64:1315–1316.
183. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases:
the phantom menace. J Antimicrob Chemother 2012;67:1597–
1606.
184. Aubert D, Naas T, Heritier C, Poirel L, Nordmann P. Functional
characterization of IS1999, an IS4 family element involved in
mobilization and expression of b-lactam resistance genes. J
Bacteriol 2006;188:6506–6514.
185. Poirel L, Bonnin RA, Nordmann P. Genetic features of the wide-
spread plasmid coding for the carbapenemase OXA-48.
Antimicrob Agents Chemother 2012;56:559–562.
186. Giani T, Conte V, di Pilato V, Aschbacher R, Weber C et al.
Escherichia coli from Italy producing OXA-48 carbapenemase
encoded by a novel Tn1999 transposon derivative. Antimicrob
Agents Chemother 2012;56:2211–2213.
187. Potron A, Nordmann P, Rondinaud E, Jaureguy F, Poirel L. A
mosaic transposon encoding OXA-48 and CTX-M-15: towards
pan-resistance. J Antimicrob Chemother 2013;68:476–477.
188. Findlay J, Hopkins KL, Loy R, Doumith M, Meunier D et al. OXA-
48-like carbapenemases in the UK: an analysis of isolates and
cases from 2007 to 2014. J Antimicrob Chemother 2017;72:
1340–1349.
189. Gaibani P, Scaltriti E, Benni C, Pongolini S, Ambretti S et al.
Characterization of an IncL/M plasmid carrying blaOXA-48 in a
Klebsiella pneumoniae strain from Italy. New Microbiologica
2017;40:284–285.
190. Izdebski R, Baraniak A, Zabicka D, Machulska M, Urbanowicz P
et al. Enterobacteriaceae producing OXA-48-like carbapene-
mases in Poland, 2013-January 2017. J Antimicrob Chemother
2018;73:620–625.
191. Lutgring JD, Zhu W, de Man TJB, Avillan JJ, Anderson KF et al.
Phenotypic and genotypic characterization of Enterobacteriaceae
producing oxacillinase-48-like carbapenemases, United States.
Emerg Infect Dis 2018;24:700–709.
192. Skalova A, Chudejova K, Rotova V, Medvecky M, Studentova V
et al. Molecular characterization of OXA-48-like-producing
Enterobacteriaceae in the Czech Republic and evidence for hori-
zontal transfer of pOXA-48-like plasmids. Antimicrob Agents
Chemother 2016;61: e01889-16.
193. Yu F, Wang S, Lv J, Qi X, Guo Y et al. Coexistence of OXA-48-
producing Klebsiella pneumoniae and Escherichia coli in a hospi-
talized patient who returned from Europe to China. Antimicrob
Agents Chemother 2017;61:e02580-16.
194. Balkan II, Aygün G, Aydın S, Mutcalı SI, Kara Z et al. Blood
stream infections due to OXA-48-like carbapenemase-producing
Enterobacteriaceae: treatment and survival. Int J Infect Dis 2014;
26:51–56.
195. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN
et al. Early dissemination of NDM-1- and OXA-181-producing
Enterobacteriaceae in Indian hospitals: report from the SENTRY
antimicrobial surveillance program, 2006–2007. Antimicrob
Agents Chemother 2011;55:1274–1278.
196. Decousser JW, Poirel L, Desroches M, Jayol A, Denamur E
et al. Failure to detect carbapenem-resistant Escherichia coli
producing OXA-48-like using the Xpert Carba-R assay®. Clin
Microbiol Infect 2015;21:e9–e10.
197. Kalpoe JS, Al Naiemi N, Poirel L, Nordmann P. Detection of an
Ambler class D OXA-48-type b-lactamase in a Klebsiella pneu-
moniae strain in The Netherlands. J Med Microbiol 2011;60:677–
678.
198. Potron A, Nordmann P, Lafeuille E, Al Maskari Z, Al Rashdi F
et al. Characterization of OXA-181, a carbapenem-hydrolyzing
class D b-lactamase from Klebsiella pneumoniae. Antimicrob
Agents Chemother 2011;55:4896–4899.
199. Williamson DA, Heffernan H, Sidjabat H, Roberts SA, Paterson
DL et al. Intercontinental transfer of OXA-181-producing
Klebsiella pneumoniae into New Zealand. J Antimicrob Chemother
2011;66:2888–2890.
200. Cho SY, Huh HJ, Baek JY, Chung NY, Ryu JG et al. Klebsiella
pneumoniae co-producing NDM-5 and OXA-181 carbapene-
mases, South Korea. Emerg Infect Dis 2015;21:1088–1089.
201. Gamal D, Fernandez-Martínez M, El-Defrawy I, Ocampo-Sosa
AA, Martínez-Martínez L. First identification of NDM-5 associ-
ated with OXA-181 in Escherichia coli from Egypt. Emerg
Microbes Infect 2016;5:e30.
202. Overballe-Petersen S, Roer L, Ng K, Hansen F, Justesen US
et al. Complete nucleotide sequence of an Escherichia coli
sequence type 410 strain carrying blaNDM-5 on an IncF multidrug
resistance plasmid and blaOXA-181 on an IncX3 Plasmid. Genome
Announc 2018;6:e01542-17.
203. Adriaenssens N, Coenen S, Versporten A, Muller A, Minalu G
et al. European surveillance of antimicrobial consumption
(ESAC): outpatient antibiotic use in Europe (1997–2009). J
Antimicrob Chemother 2011;66:vi3–vi12.
204. Arcilla MS, van Hattem JM, Haverkate MR, Bootsma MCJ, van
Genderen PJJ et al. Import and spread of extended-spectrum
b-lactamase-producing Enterobacteriaceae by international trav-
ellers (COMBAT study): a prospective, multicentre cohort study.
Lancet Infect Dis 2017;17:78–85.
205. Bengtsson-Palme J, Angelin M, Huss M, Kjellqvist S,
Kristiansson E et al. The human gut microbiome as a trans-
porter of antibiotic resistance genes between continents.
Antimicrob Agents Chemother 2015;59:6551–6560.
206. Lübbert C, Straube L, Stein C, Makarewicz O, Schubert S et al.
Colonization with extended-spectrum b-lactamase-producing
and carbapenemase-producing Enterobacteriaceae in interna-
tional travelers returning to Germany. Int J Med Microbiol 2015;
305:148–156.
207. Ruppe E, Armand-Lefevre L, Estellat C, Consigny PH, El Mniai A
et al. High rate of acquisition but short duration of carriage of
multidrug-resistant Enterobacteriaceae after travel to the
tropics. Clin Infect Dis 2015;61:593–600.
208. von Wintersdorff CJ, Penders J, Stobberingh EE, Oude Lashof
AM, Hoebe CJ et al. High rates of antimicrobial drug resistance
gene acquisition after international travel, The Netherlands.
Emerg Infect Dis 2014;20:649–657.
209. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R et al. Emergence of
plasmid-mediated colistin resistance mechanism MCR-1 in ani-
mals and human beings in China: a microbiological and molecu-
lar biological study. Lancet Infect Dis 2016;16:161–168.
210. European Centre for Disease Prevention and Control. Summary
of the Latest Data on Antibiotic Consumption in the European
Union. Stockholm: European Centre for Disease Prevention and
Control; 2017.
211. Zheng B, Dong H, Xu H, Lv J, Zhang J et al. Coexistence of MCR-
1 and NDM-1 in clinical Escherichia coli isolates. Clin Infect Dis
2016;63:1393–1395.
212. Newton-Foot M, Snyman Y, Maloba MRB, Whitelaw AC. Plas-
mid-mediated mcr-1 colistin resistance in Escherichia coli and
Klebsiella spp. clinical isolates from the Western Cape region of
South Africa. Antimicrob Resist Infect Control 2017;6:78.
213. Tian G-B, Doi Y, Shen J, Walsh TR, Wang Y et al. MCR-1-produc-
ing Klebsiella pneumoniae outbreak in China. Lancet Infect Dis
2017;17:577.
214. Li A, Yang Y, Miao M, Chavda KD, Mediavilla JR et al. Complete
sequences of mcr-1-harboring plasmids from extended-
spectrum-b-lactamase- and carbapenemase-producing Entero-
bacteriaceae. Antimicrob Agents Chemother 2016;60:4351–4354.
215. Skov RL, Monnet DL. Plasmid-mediated colistin resistance
(mcr-1 gene): three months later, the story unfolds. Euro Surveill
2016;21:30155.
216. Schwarz S, Johnson AP. Transferable resistance to colistin: a
new but old threat. J Antimicrob Chemother 2016;71:2066–2070.
Wilson and Török, Microbial Genomics 2018;4
12
Downloaded from www.microbiologyresearch.org by
IP:  81.96.234.119
On: Wed, 01 Aug 2018 09:31:09
217. Snesrud E, He S, Chandler M, Dekker JP, Hickman AB et al. A
model for transposition of the colistin resistance gene mcr-1 by
ISApl1. Antimicrob Agents Chemother 2016;60:6973–6976.
218. Poirel L, Kieffer N, Nordmann P. In vitro study of ISApl1-medi-
ated mobilization of the colistin resistance gene mcr-1.
Antimicrob Agents Chemother 2017;61:e00127-17.
219. Snesrud E, McGann P, Chandler M. The birth and demise of the
ISApl1-mcr-1-ISApl1 composite transposon: the vehicle for
transferable colistin resistance. MBio 2018;9:e02381-17.
220. Beyrouthy R, Robin F, Lessene A, Lacombat I, Dortet L et al.
MCR-1 and OXA-48 in vivo acquisition in KPC-producing
Escherichia coli after colistin treatment. Antimicrob Agents
Chemother 2017;61:e02540-16.
221. McGann P, Snesrud E, Maybank R, Corey B, Ong AC et al.
Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF
plasmid: first report of mcr-1 in the United States. Antimicrob
Agents Chemother 2016;60:4420–4421.
222. Mediavilla JR, Patrawalla A, Chen L, Chavda KD, Mathema B
et al. Colistin- and carbapenem-resistant Escherichia coli har-
boring mcr-1 and blaNDM-5, causing a complicated urinary tract
infection in a patient from the United States. MBio 2016;7:
e01191-16.
223. Wang Y, Tian GB, Zhang R, Shen Y, Tyrrell JM et al. Prevalence,
risk factors, outcomes, and molecular epidemiology of mcr-1-
positive Enterobacteriaceae in patients and healthy adults from
China: an epidemiological and clinical study. Lancet Infect Dis
2017;17:390–399.
224. Yao X, Doi Y, Zeng L, Lv L, Liu JH. Carbapenem-resistant and
colistin-resistant Escherichia coli co-producing NDM-9 and MCR-
1. Lancet Infect Dis 2016;16:288–289.
225. Shen Z, Wang Y, Shen Y, Shen J, Wu C. Early emergence of
mcr-1 in Escherichia coli from food-producing animals. Lancet
Infect Dis 2016;16:293.
226. Malhotra-Kumar S, Xavier BB, Das AJ, Lammens C, Hoang HT
et al. Colistin-resistant Escherichia coli harbouring mcr-1 iso-
lated from food animals in Hanoi, Vietnam. Lancet Infect Dis
2016;16:286–287.
227. Wang R, van Dorp L, Shaw LP, Bradley P, Wang Q et al. The
global distribution and spread of the mobilized colistin resis-
tance gene mcr-1. Nat Commun 2018;9:1179.
228. European Medicines Agency. European Surveillance of Veterinary
Antimicrobial Consumption – Sales of Veterinary Antimicrobial
Agents in 30 European Countries in 2015. London: European Med-
icines Agency; 2017.
229. Walsh TR, Wu Y. China bans colistin as a feed additive for ani-
mals. Lancet Infect Dis 2016;16:1102–1103.
230. World Health Organization. United Nations meeting on antimi-
crobial resistance. Bull World Health Organ 2016;94:638–639.
231. United Nations General Assembly. Political Declaration of the
High-level Meeting of the General Assembly on Antimicrobial
Resistance. New York: United Nations; 2016.
232. Australian Government DoH, Department of Agriculture.
Responding to the Threat of Antimicrobial Resistance. Canberra:
Australian Government; 2015.
233. European Commission. A European One Health Action Plan
Against Antimicrobial Resistance (AMR). Brussels: European
Commission; 2017.
234. UK Department of Health. UK Five Year Antimicrobial Resistance
Strategy 2013-2018. London: UK Department of Health; 2013.
235. The White House. National Strategy for Combating Antibiotic-
Resistant Bacteria. Washington, DC: The White House; 2014.
236. Giacobbe DR, Del Bono V, Mikulska M, Gustinetti G, Marchese A
et al. Impact of a mixed educational and semi-restrictive antimi-
crobial stewardship project in a large teaching hospital in
Northern Italy. Infection 2017;45:849–856.
237. Molina J, Peñalva G, Gil-Navarro MV, Praena J, Lepe JA et al.
Long-term impact of an educational antimicrobial stewardship
program on hospital-acquired candidemia and multidrug-
resistant bloodstream infections: a quasi-experimental study of
interrupted time-series analysis. Clin Infect Dis 2017;65:1992–
1999.
238. Pulcini C, Binda F, Lamkang AS, Trett A, Charani E et al. Devel-
oping core elements and checklist items for global hospital anti-
microbial stewardship programmes: a consensus approach. Clin
Microbiol Infect 2018.
239. Robinson TP, Bu DP, Carrique-Mas J, Fevre EM, Gilbert M et al.
Antibiotic resistance is the quintessential One Health issue.
Trans R Soc Trop Med Hyg 2016;110:377–380.
240. World Health Organization, Food and Agriculture Organization
of the United Nations, World Organization for Animal Health.
Antimicrobial Resistance – A Manual for Developing National
Action Plans. Geneva: World Health Organization; 2016.
241. Pouwels KB, Dolk FCK, Smith DRM, Robotham JV, Smieszek T.
Actual versus ’ideal’ antibiotic prescribing for common condi-
tions in English primary care. J Antimicrob Chemother 2018;
7319–26.
242. Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA
et al. Prevalence of inappropriate antibiotic prescriptions among
US ambulatory care visits, 2010–2011. JAMA 2016;315:1864–
1873.
243. Bin Abdulhak AA, Altannir MA, Almansor MA, Almohaya MS,
Onazi AS et al. Non prescribed sale of antibiotics in Riyadh,
Saudi Arabia: a cross sectional study. BMC Public Health 2011;
11:538.
244. Kalungia AC, Burger J, Godman B, Costa JO, Simuwelu C. Non-
prescription sale and dispensing of antibiotics in community
pharmacies in Zambia. Expert Rev Anti Infect Ther 2016;14:
1215–1223.
245. Kotwani A, Wattal C, Joshi PC, Holloway K. Irrational use of
antibiotics and role of the pharmacist: an insight from a qualita-
tive study in New Delhi, India. J Clin Pharm Ther 2012;37:308–
312.
246. Nga Dott, Chuc NT, Hoa NP, Hoa NQ, Nguyen NT et al. Antibiotic
sales in rural and urban pharmacies in northern Vietnam: an
observational study. BMC Pharmacol Toxicol 2014;15:6.
247. European Centre for Disease Prevention and Control. ECDC/
EFSA/EMA second joint report on the integrated analysis of the
consumption of antimicrobial agents and occurrence of antimi-
crobial resistance in bacteria from humans and food-producing
animals. EFSA J 2017;15:4872.
248. van Boeckel TP, Brower C, Gilbert M, Grenfell BT, Levin SA
et al. Global trends in antimicrobial use in food animals. Proc
Natl Acad Sci USA 2015;112:5649–5654.
249. US Food and Drug Administration. 2016 Summary Report on
Antimicrobials Sold or Distributed of Use in Food-producing
Animals. Silver Spring, MD: US Food and Drug Administration;
2017.
250. Mataseje LF, Boyd DA, Delport J, Hoang L, Imperial M et al. Ser-
ratia marcescens harbouring SME-type class A carbapenemases
in Canada and the presence of blaSME on a novel genomic
island, SmarGI1-1. J Antimicrob Chemother 2014;69:1825–1829.
251. Hopkins KL, Findlay J, Doumith M, Mather B, Meunier D et al.
IMI-2 carbapenemase in a clinical Klebsiella variicola isolated in
the UK. J Antimicrob Chemother 2017;72:2129–2131.
252. Rojo-Bezares B, Martín C, López M, Torres C, Saenz Y. First
detection of blaIMI-2 gene in a clinical Escherichia coli strain.
Antimicrob Agents Chemother 2012;56:1146–1147.
253. Rasmussen BA, Bush K, Keeney D, Yang Y, Hare R et al. Char-
acterization of IMI-1 b-lactamase, a class A carbapenem-
hydrolyzing enzyme from Enterobacter cloacae. Antimicrob
Agents Chemother 1996;40:2080–2086.
254. Carattoli A. Plasmids and the spread of resistance. Int J Med
Microbiol 2013;303:298–304.
Wilson and Török, Microbial Genomics 2018;4
13
Downloaded from www.microbiologyresearch.org by
IP:  81.96.234.119
On: Wed, 01 Aug 2018 09:31:09
255. Espedido BA, Partridge SR, Iredell JR. blaIMP-4in different
genetic contexts in Enterobacteriaceae isolates from Australia.
Antimicrob Agents Chemother 2008;52:2984–2987.
256. Peleg AY, Franklin C, Bell JM, Spelman DW. Dissemination of
the metallo-b-lactamase gene blaIMP-4 among gram-negative
pathogens in a clinical setting in Australia. Clin Infect Dis 2005;
41:1549–1556.
257. Tato M, Coque TM, Baquero F, Cantón R. Dispersal of carbape-
nemase blaVIM-1 gene associated with different Tn402 variants,
mercury transposons, and conjugative plasmids in Enterobacter-
iaceae and Pseudomonas aeruginosa. Antimicrob Agents
Chemother 2010;54:320–327.
258. Loli A, Tzouvelekis LS, Tzelepi E, Carattoli A, Vatopoulos AC
et al. Sources of diversity of carbapenem resistance levels in
Klebsiella pneumoniae carrying blaVIM-1. J Antimicrob Chemother
2006;58:669–672.
259. Luzzaro F, Docquier JD, Colinon C, Endimiani A, Lombardi G
et al. Emergence in Klebsiella pneumoniae and Enterobacter cloa-
cae clinical isolates of the VIM-4 metallo-b-lactamase encoded
by a conjugative plasmid. Antimicrob Agents Chemother 2004;48:
648–650.
260. Rieber H, Frontzek A, Pfeifer Y. Emergence of metallo-b-lacta-
mase GIM-1 in a clinical isolate of Serratia marcescens.
Antimicrob Agents Chemother 2012;56:4945–4947.
261. Sekiguchi J, Morita K, Kitao T, Watanabe N, Okazaki M et al.
KHM-1, a novel plasmid-mediated metallo-b-lactamase from a
Citrobacter freundii clinical isolate. Antimicrob Agents Chemother
2008;52:4194–4197.
Wilson and Török, Microbial Genomics 2018;4
14
Five reasons to publish your next article with a Microbiology Society journal
1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around
the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.
Find out more and submit your article at microbiologyresearch.org.
